Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26255871 | 1.00 | CRBN (0.48) | CRBNDDB1DRD2SUV39H2JAK2 | |
| SCHEMBL26255701 | 0.94 | CRBN (0.48) | CRBNDDB1DRD2SUV39H2JAK2 | |
| SCHEMBL25141804 | 0.85 | DDB1 (0.53) | CRBNDDB1 | |
| SCHEMBL30905908 | 0.85 | DDB1 (0.53) | CRBNDDB1 | |
| SCHEMBL24861357 | 0.83 | DRD2 (0.42) | CRBNDDB1DRD2SUV39H2JAK2 | |
| SCHEMBL29024450 | 0.83 | CRBN (0.41) | CRBNDDB1 | |
| SCHEMBL24861164 | 0.82 | CRBN (0.45) | CRBNDDB1 | |
| SCHEMBL30741730 | 0.80 | CRBN (0.68) | CRBNDDB1DRD2 | |
| SCHEMBL22291243 | 0.80 | CRBN (0.68) | CRBNDDB1DRD2 | |
| SCHEMBL30905936 | 0.80 | CRBN (0.49) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, PSMC1, PSME3 | CRBN 1/4885DDB1 2515/4885DRD2 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.